Global Apixaban Market, By Form (Capsule, Tablets), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Apixaban market is expected to reach at an estimated value of USD 2,602.97 million and grow at a potential rate of 5.22% in the forecast period of 2021 to 2028. Increasing prevalence of venous thromboembolism related conditions is the vital factor escalating the market growth.
Apixaban is a type of food and drug administrator (FDA) approved anticoagulant which is used for the treatment of venous thromboembolic events (blood clot) that forms within a vein. Venous thromboembolic events (VTE) can occur without any prior symptoms or warning signs and can go unrecognized and undiagnosed by a healthcare professional. Symptoms that do appear may be associated with either deep vein thrombosis (DVT) or either pulmonary embolism (PE) such as pain in the calf, swelling in the ankle or foot, redness or noticeable discoloration spots, rapid breathing, chest pain, and others. Apixaban is generally indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Rising therapeutic indications for apixaban will uplift the market growth, also rise in the prevalence of atrial fibrillation, venous thromboembolism and stroke, increase in number of geriatric population, rise in prevalence of obesity, rising surge in healthcare expenditures worldwide and increasing government and private organizations are significantly investing capital in healthcare research and development are some of the crucial factors among others driving the apixaban market. Moreover, rising potential in emerging economies and increasing technological advancements and rising modernization in the healthcare sector will further create new opportunities for the apixaban market in the forecast period of 2021-2028.
However, rising price of NOACs and increasing poor demand in under developed countries are the major factors among others acting as restraints, and will further challenge the apixaban market in the forecast period mentioned above.
This apixaban market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To gain more info on apixaban market contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Apixaban Market Scope and Market Size
Apixaban market is segmented on the basis of form and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of form, the apixaban market is segmented into capsule and tablets.
- Apixaban market is also segmented on the basis of distribution channel into hospitals, clinics, retail pharmacies, and online pharmacies.
Global Apixaban Market Country Level Analysis
Apixaban market is analysed and market size information is provided by country, form and distribution channel as referenced above.
The countries covered in the apixaban market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Asia-Pacific dominates the apixaban market due to the increasing healthcare initiatives by respective governments, increase in number of geriatric population, rise in prevalence of obesity and rising surge in healthcare expenditures worldwide and increasing government and private organizations in this region. Europe is the expected region in terms of growth in apixaban market due to rising prevalence of venous thromboembolism related conditions, rising therapeutic indications for apixaban, rising surge in healthcare expenditures worldwide and increasing government and private organizations are significantly investing capital in healthcare research and development in this region.
The country section of the apixaban market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Apixaban market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Apixaban Market Share Analysis
Apixaban market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to apixaban market.
The major players covered in the apixaban market report are Abbott., Sanofi, Pfizer Inc, F. Hoffmann-La Roche Ltd , Mylan N.V., Aspen Holdings, Bristol Myers Squibb Company, Eisai Co., Ltd., Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., Novartis AG, OPOCRIN S.P.A, SARIA SE & Co. KG, Shanghai Fosun Pharmaceutical (Group) Co., Ltd, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd, Teva Pharmaceutical Industries Ltd. and Yino Pharma Limited among other domestic and global players. regenerative medicine market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Apixaban Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.